KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Total Current Liabilities (2023 - 2025)

Biocryst Pharmaceuticals' Total Current Liabilities history spans 9 years, with the latest figure at $196.1 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 22.25% year-over-year to $196.1 million; the TTM value through Dec 2025 reached $196.1 million, up 22.25%, while the annual FY2025 figure was $196.1 million, 22.25% up from the prior year.
  • Total Current Liabilities reached $196.1 million in Q4 2025 per BCRX's latest filing, up from $190.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $196.1 million in Q4 2025 to a low of $85.2 million in Q1 2023.
  • Average Total Current Liabilities over 3 years is $140.5 million, with a median of $144.9 million recorded in 2023.
  • The largest YoY upside for Total Current Liabilities was 69.2% in 2024 against a maximum downside of 6.93% in 2024.
  • A 3-year view of Total Current Liabilities shows it stood at $150.0 million in 2023, then grew by 6.93% to $160.4 million in 2024, then rose by 22.25% to $196.1 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Total Current Liabilities are $196.1 million (Q4 2025), $190.2 million (Q3 2025), and $177.2 million (Q2 2025).